Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | BMC Cancer

Fig. 1

From: NPM1 as a potential therapeutic target for atypical teratoid/rhabdoid tumors

Fig. 1

Biallelic inactivation and expression changes of SMARCB1. a Copy number changes in SMARCB1 exons on chromosome 22 of 4 AT/RT samples in whole exome capture sequencing. All 4 tumor samples showed loss of heterozygosity (heterozygous in the normal tissue but homozygous in the tumor tissue) based on variant allele fraction values. b Expression differences between the AT/RT samples and the control samples analyzed in whole transcriptome sequencing (p-value = 2.69E-05). Normalized reads per kilobase per million mapped reads (RPKM) values revealed a significant decrease in AT/RT samples compared with normal brain samples

Back to article page